Expression Analysis, Inc., a leading provider of genomic services for clinical trials and research has entered into a partnership with Sunderland based Complement Genomics Ltd. to offer its genomic services to the UK market. By partnering with an established company, Expression Analysis will gain access to clients beyond its primary market in the US.

The Geneblitz unit offers state-of-the-art molecular services to pharmaceutical companies, governmental agencies, universities and research institutes. The partnership will give Expression Analysis access to these clients and will allow both companies to expand their service offerings.

"The partnership with Geneblitz provides us an established presence in the United Kingdom, with an experienced service provider who operates with the same philosophy and similar quality standards and platforms," stated Steve McPhail, president and CEO of Expression Analysis. Geneblitz will focus its efforts on Genome-Wide Association studies which have become an increasingly larger part of our business, continued McPhail.

"Expression Analysis is an industry leader with a great reputation in the field of genomic services and our decision to partner with them was not a difficult one," said Louise Allcroft, chief executive officer of Complement Genomics Ltd. "By combining our experience, scientific leadership and high-throughput capabilities, we will be able to help meet the needs of the extensive pharmaceutical and biotechnology infrastructure in the United Kingdom."

Expertise Beyond Expression — Providing whole genome to focused set gene expression and genotyping assays, along with sequencing services using Affymetrix, Illumina and Applied Biosystems. A leading provider of genomic services in clinical trials and research, Expression Analysis offers solutions for challenging specimens such as blood and FFPE tissue specimens as well as nucleic acid isolation and bioinformatic services.

Complement Genomics Ltd provides molecular and bioanalytical services under its Geneblitz brand. Geneblitz provides a comprehensive range of services to the biotechnology sector such as genotyping (including pharmacogenetic screening), DNA sequencing, forensic (human identity) testing and a number of toxicology and drug analysis protocols in addition to its own research programs in woundcare.